暫無數據
代碼股票名稱
最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業
美股期權個股詳情
AXNX240517C72500
- 0.05
- 0.000.00%
延時15分鐘行情交易中 05/17 12:16 (美東)
0.00最高價0.00最低價
0.00今開0.05昨收0張成交量291張未平倉合約數72.50行權價0.00成交額524.80%引伸波幅7.34%溢價2024/05/17到期日0.00内在价值100合約乘數-2天距到期日0.05時間價值100合約規模美式期權類型0.0446Delta0.0339Gamma1351.80槓桿倍數-5.5308Theta0.0000Rho60.23有效槓桿0.0005Vega
分時
- 5日
- 日K
新聞
Axonics 神經刺激器系統獲得澳大利亞批准
作者：本·格里克曼（Ben Glickman）Axonics週四表示，它已獲得澳大利亞監管機構的批准，可以銷售其免充電的神經刺激器設備。加利福尼亞州爾灣市總部位於醫療技術公司
澳大利亞批准Axonics植入物治療過度活躍的膀胱
Axonics（AXNX）週四晚間表示，澳大利亞監管機構已批准該公司的Axonics F15骶骨神經調節裝置，用於治療成年人的膀胱過度活躍。植入物相對較小
快訊 | Axonics獲得治療用品管理局批准在澳大利亞銷售Axonics F15
快訊 | Axonics 在澳大利亞獲得監管部門批准的免充電 SNM 系統
Needham：重申axonics（AXNX.US）持久有評級。
Needham：重申axonics（AXNX.US）持久有評級。
快訊 | Needham 重申暫停 Axonics
評論
Analysts' consensus shows Axonics performing as expected, with no major estimate changes post recent results. Despite a predicted slowdown in revenue growth, Axonics is still expected to outpace the wider industry.
Analysts Have Made A Financial Statement On Axonics, Inc.'s (NASDAQ:AXNX) Full-Year Report 1
Axonics' consistent revenue growth, despite last year's lack of profit, has led to a 33% annual increase in share price over the past five years, making it a potential investment opportunity.
Meghan Scanlon from Boston Scientific forecasts merger to enhance support for urologists handling chronic conditions. Acquisition may improve earnings per share over time, though GAAP earnings may see lesser increase due to related expenses.
Investors believe in Axonics' potential for future revenue growth, supporting higher stock prices despite a high P/S ratio. They discount the chance of a revenue decrease, but risks and other factors must also be considered.
Axonics' strong revenue growth may be driving its stock performance and could be attractive for growth investors. The recent sell-off may open up investment opportunities if long-term growth signs are positive.
閱讀更多